Latest Insider Transactions at Amylyx Pharmaceuticals, Inc. (AMLX)
This section provides a real-time view of insider transactions for Amylyx Pharmaceuticals, Inc. (AMLX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Amylyx Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Amylyx Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 06
2023
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Open market or private sale
|
Direct |
5,968
+0.1%
|
$214,848
$36.44 P/Share
|
|
Jan 06
2023
|
Margaret Olinger Chief Commercial Officer |
BUY
Open market or private sale
|
Direct |
2,403
+0.56%
|
$86,508
$36.44 P/Share
|
|
Dec 30
2022
|
James M Frates Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+12.0%
|
$30,000
$6.88 P/Share
|
|
Sep 09
2022
|
Viking Global Investors LP |
SELL
Open market or private sale
|
Indirect |
700,000
-3.7%
|
$21,000,000
$30.74 P/Share
|
|
Sep 08
2022
|
Viking Global Investors LP |
SELL
Open market or private sale
|
Indirect |
700,000
-2.03%
|
$20,300,000
$29.48 P/Share
|
|
Jul 06
2022
|
Invest 1 B.V. Als > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
60,609
-0.26%
|
$1,212,180
$20.97 P/Share
|
|
May 05
2022
|
Joshua B Cohen Co-Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
334,520
+10.35%
|
$0
$0.37 P/Share
|
|
May 05
2022
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
334,520
+10.35%
|
$0
$0.37 P/Share
|
|
Feb 22
2022
|
Gina Mazzariello Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
41,000
+50.0%
|
-
|
|
Jan 11
2022
|
Invest 1 B.V. Als > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
5,955,889
+47.38%
|
-
|
|
Jan 11
2022
|
Morningside Venture Investments LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
263,158
+2.41%
|
$5,000,002
$19.0 P/Share
|
|
Jan 11
2022
|
Morningside Venture Investments LTD > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
10,415,650
+50.0%
|
-
|
|
Jan 11
2022
|
Viking Global Investors LP |
BUY
Open market or private purchase
|
Indirect |
2,300,000
+50.0%
|
$43,700,000
$19.0 P/Share
|
|
Jan 11
2022
|
Viking Global Investors LP |
BUY
Conversion of derivative security
|
Indirect |
4,870,536
+50.0%
|
-
|
|
Jan 06
2022
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+2.84%
|
-
|
|
Jan 06
2022
|
Justin B. Klee Co-Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
4,870
+0.2%
|
-
|
|
Jan 06
2022
|
James M Frates Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,667
+50.0%
|
-
|
|
Jan 06
2022
|
Margaret Olinger Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
6,842
+3.06%
|
$129,998
$19.0 P/Share
|
|
Jan 06
2022
|
Margaret Olinger Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,333
+11.89%
|
-
|
|
Jan 06
2022
|
Joshua B Cohen Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+2.84%
|
-
|
|
Jan 06
2022
|
Joshua B Cohen Co-Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
4,870
+0.2%
|
-
|
|
Jan 06
2022
|
George M Milne Jr |
BUY
Open market or private purchase
|
Direct |
26,315
+10.62%
|
$499,985
$19.0 P/Share
|
|
Jan 06
2022
|
Patrick D Yeramian Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
28,333
+12.07%
|
-
|
|
Jan 06
2022
|
Isaac Cheng Director |
BUY
Open market or private purchase
|
Direct |
6,578
+50.0%
|
$124,982
$19.0 P/Share
|
|
Jan 06
2022
|
Isaac Cheng Director |
BUY
Conversion of derivative security
|
Indirect |
10,415,650
+29.62%
|
-
|
|
Jan 06
2022
|
Paul R. Fonteyne |
BUY
Open market or private purchase
|
Direct |
3,947
+50.0%
|
$74,993
$19.0 P/Share
|